These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38542045)

  • 1. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
    Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
    [No Abstract]   [Full Text] [Related]  

  • 2. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH; Song GG
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis.
    Benucci M; Gobbi FL; Fusi P; Damiani A; Russo E; Guiducci S; Manfredi M; Grossi V; Infantino M; Amedei A
    Front Biosci (Landmark Ed); 2023 Aug; 28(8):176. PubMed ID: 37664943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
    Lee YH; Song GG
    Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).
    Benucci M; Bardelli M; Cazzato M; Bartoli F; Damiani A; Li Gobbi F; Bandinelli F; Panaccione A; Di Cato L; Niccoli L; Frediani B; Mosca M; Guiducci S; Cantini F
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39063966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
    Cai W; Tong R; Sun Y; Yao Y; Zhang J
    Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
    Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.
    Farnos C; Barbier V; Doussiere M; Deprez V; Hamidou Y; Bruy PA; Sobhy Danial JM; Goeb V
    J Clin Med; 2024 Aug; 13(16):. PubMed ID: 39200750
    [No Abstract]   [Full Text] [Related]  

  • 17. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
    González-Freire L; Giménez-Candela RM; Castro-Luaces S; Veiga-Villaverde AB; Crespo-Diz C
    Farm Hosp; 2021 Jun; 45(4):165-169. PubMed ID: 34218760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.
    Balsa A; Wassenberg S; Tanaka Y; Tournadre A; Orzechowski HD; Rajendran V; Lendl U; Stiers PJ; Watson C; Caporali R; Galloway J; Verschueren P
    Rheumatol Ther; 2023 Dec; 10(6):1555-1574. PubMed ID: 37747626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.